Keywords
Antimicrobials
Defined daily dose
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To describe and compare the profile of antimicrobial use during the two waves of COVID-19 in a public hospital located in the city of Manaus, Amazonas. Methods: This is a descriptive and retrospective study conducted at a university hospital in Manaus, where data from medical records, prescriptions, and request forms for the use of antimicrobials were collected. The use of antimicrobials was measured according to the Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) methodology. Results: During the first wave period, the most consumed antimicrobial was ceftriaxone (DDD 1352.01), followed by piperacillin-tazobactam (DDD 1245.56), cefepime (DDD 1191.23) and meropenem (DDD 1139.88). In the second wave, the most consumed antimicrobial continued to be ceftriaxone, with an even higher consumption (DDD 2010.55), followed by meropenem (DDD 1592.22), vancomycin (DDD 722.72) and piperacillin-tazobactam (DDD 704.82). Conclusion: The COVID-19 pandemic has impacted the consumption of different classes of antimicrobials, with a notable emphasis on cephalosporins and broad-spectrum beta-lactams. These findings highlight the vital importance of careful surveillance and constant monitoring of antimicrobial consumption during periods of health crisis, such as the COVID-19 pandemic.
References
BADIN RC, et al. Clinical and pharmacological factors associated with mortality in patients with COVID-19 in a high complexity hospital in Manaus: A retrospective study. Plos one, 2023; 18(2): e0280891.
BARRETO ICHC, et al. Colapso na saúde em Manaus: o fardo de não aderir às medidas não farmacológicas de redução da transmissão da Covid-19. Saúde em debate, 2021; 45: 1126-1139.
BRASIL. Boletins epidemiológicos do Ministério da Saúde. 2020. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos. Acessado em: 05 de junho de 2023.
BUEHRLE DJ, et al. Antibiotic consumption and stewardship at a hospital outside of an early coronavirus disease 2019 epicenter. Antimicrobial Agents and Chemotherapy, 2020; 64(11): 10-1128.
BUSS LF, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science, 2021; 371(6526): 288–292.
CASTRO-LOPES A, et al. Increase of antimicrobial consumption in a tertiary care hospital during the first phase of the COVID-19 pandemic. Antibiotics, 2021; 10(7): 778.
COUTINHO RM, et al. Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant. Communications Medicine, 2021; 1(1): 48.
DE MORAES SS e BADIN, RC. Perfil do uso de antifúngicos sistêmicos em uma Unidade de Terapia Intensiva de um hospital de alta complexidade. Research, Society and Development, 2022; 11 (6): e4711628385-e4711628385.
FARIA N, et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Virological, 2021; 372: 815-821.
FREITAS ARR, et al. The emergence of novel SARS-CoV-2 variant P.1 in Amazonas (Brazil) was temporally associated with a change in the age and gender profile of COVID-19 mortality. The Lancet Regional Health–Americas, 2021; 1.
GARCIA-VIDAL C, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clinical Microbiology and Infection, 2021; 27(1): 83–88.
GRAU S, et al. antimicrobial consumption among 66 acute care hospitals in Catalonia: impact of the COVID-19 pandemic. Antibiotics, 2021; 10(8): 943.
HAMIDI AA e YILMAZ, Ş. Antibiotic consumption in the hospital during COVID-19 pandemic, distribution of bacterial agents and antimicrobial resistance: A single-center study. Journal of Surgery and Medicine, 2021; 5(2): 124-127.
HE D, et al. Resolving the enigma of Iquitos and Manaus: A modeling analysis of multiple COVID-19 epidemic waves in two Amazonian cities. Proceedings of the National Academy of Sciences, 2023; 120(10): e2211422120.
HUGHES S, et al. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clinical Microbiology and Infection, 2020; 26(10):1395–1399.
KANJ SS, et al. The battle against fungi: lessons in antifungal stewardship from COVID 19 times. International Journal of Antimicrobial Agents, 2023; 62(1):106846.
KAYAASLAN B, et al. Characteristics of candidemia in COVID‐19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non‐COVID‐19 patients. Myc, 2021; 64(9): 1083-1091.
KHAN S, et al. antimicrobial consumption in patients with COVID-19: a systematic review and meta-analysis. Expert Review of Anti-infective Therapy, 2022; 20(5): 749-772.
KOW CS, HASAN SS. Azithromycin in patients with COVID-19: Friend or foe? Clinical Microbiology and Infection, 2021; 27(1): 136-137.
KARAMI Z, et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infectious Diseases, 2021; 53(2): 102–110.
LANGFORD BJ, et al. Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2023; 29(3): 302-309.
MARINHO MG, et al. Estudo de consumo de antimicrobianos do Centro de Terapia Intensiva de um hospital Universitário da Região Norte. Research, Society and Development, 2022; 11(5): e0611527592-e0611527592.
MESQUITA RF, et al. Uso racional de antimicrobianos e impacto no perfil de resistência microbiológica em tempos de pandemia pela Covid-19. Research, Society and Development, 2022; 11(1): e58211125382-e58211125382.
MONNET DL, HARBARTH S. Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance? Eurosurveillance, 2020; 25(45): 2001886.
MURGADELLA-SANCHO A; et al. Impact of the strategies implemented by an antimicrobial stewardship program on the antibiotic consumption in the coronavirus disease 2019 (COVID-19) pandemic. Infection Control & Hospital Epidemiology, 2022; 43(9): 1292-1293.
NAVECA FG et al. COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P. 1 emergence. Nature medicine, 2021; 27(7): 1230-1238.
NOUVELLET P, et al. Reduction in mobility and COVID-19 transmission. Nature communications, 2021; 12(1): 1090.
ONZI OS, et al. Avaliação do consumo de antimicrobianos injetáveis de um hospital privado no ano de 2009. Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde, 2011; 2(2): 20-25.
RIBEIRO AR, SOUSA NA. Besides the climate model, other variables driving the COVID-19 spread in Brazil. The Science of the Total Environment, 2020; 737: 140211.
RICHARDS DM, et al. Ceftriaxone: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs, 1984; 27: 469-527.
TANG Y, et al. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Frontiers in immunology, 2020; 11: 1708.
UL MUSTAFA Z, et al. antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. SN comprehensive clinical medicine, 2021; 3(8): 1691-1695.
URBÁNEK K, et al. Influence of third‐generation cephalosporin utilization on the occurrence of ESBL‐positive Klebsiella pneumoniae strains. Journal of clinical pharmacy and therapeutics, 2007; 32(4): 403-408.